Adma Biologics | ADMA - Selling And Administration Expenses


Adma Biologics reported $20.19M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Adma Biologics USD 20.19M 2.86M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Novavax USD 25.53M 1.34M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Takeda JPY 282.78B 29.23B Dec/2025